2017. Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial. SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s129. DOI:https://doi.org/10.25251/skin.1.supp.128.